Nisha Pandey

Wegovy More Likely To Cause Rare Blindness Than Ozempic And Other Similar Drugs, Recent Study Finds

A new safety analysis has found that <span>Wegovy</span>, the recently launched blockbuster weight loss medication containing semaglutide, may cause a rare but dangerous eye condition that can lead to sudden and permanent vision loss. 

The analysis, published in the <span>British Journal of Ophthalmology</span>, compared Wegovy, semaglutide tablets and other GLP-1 drugs like <span>Ozempic</span> by examining more than 30 million reports from the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) submitted between 2017 and 2024. 

Scientists found a safety signal that linked semaglutide medicines to non-arteritic anterior ischemic optic neuropathy (NAION), also known as eye stroke.

<h2>Wegovy More Likely To Cause Blindness Than Ozempic </h2>

The signal appeared to be nearly five times stronger for <a href="https://www.healthandme.com/health-news/ozempic-wegovy-manufacturer-to-evaluate-long-acting-semaglutide-implant-that-could-last-up-to-a-year-article-155008688" data-type="tilCustomLink">Wegovy</a> than for Ozempic, despite both medicines containing the same active ingredient, semaglutide. 

NAION occurs when blood flow to the optic nerve suddenly gets reduced, causing damage to the nerve responsible for transmitting visual information from the eye to the brain. The patient experiences painless vision loss in one eye. 

While some patients experience partial improvement, the vision loss is frequently permanent. There is currently no proven treatment to reverse the damage. 

Researchers state that the findings do not prove that Wegovy causes NAION. Instead, they observe a typical signal, meaning an unexpected pattern observed in a large safety database that requires immediate further investigation. 

Such pharmacological analyses are useful for identifying rare and adverse side effects that may not emerge during clinical trials.

<h2>Why Wegovy Poses A Greater Risk Of Rare Blindness? </h2>

Also read: <a href="https://www.healthandme.com/health-news/novo-nordisk-launches-awiqli-in-india-all-about-the-worlds-first-once-weekly-insulin-article-155014550" data-type="tilCustomLink">Novo Nordisk Launches Awiqli In India: All About The World's First Once-Weekly Insulin</a>

The stronger link observed with <span>Wegovy and NAION</span> compared with <a href="https://www.healthandme.com/health-news/glp-1-weight-loss-drug-use-nearly-quadruples-in-the-us-since-2024-as-obesity-rate-continues-to-decline-article-154974553" data-type="tilCustomLink">Ozempic</a> has also raised new questions. Both drugs contain semaglutide, but Wegovy is prescribed at higher doses for obesity, while Ozempic is used to treat type 2 diabetes. 

Researchers say that factors such as higher dosing, differences in patient populations, or underlying health conditions could help explain the disparity, although more research is needed. 

The latest findings build on growing scientific interest in the potential eye-related risks of GLP-1 receptor agonists. 

Previous observational studies have also reported an increased risk of NAION among semaglutide users, prompting regulators in Europe to add the condition as a very rare side effect to semaglutide product information last year. 

Health experts emphasize that patients should not stop taking Wegovy without consulting their healthcare provider. For most users, the drug's benefits in managing obesity and reducing associated health risks are likely to outweigh the extremely rare risk of developing NAION. 

However, anyone taking Wegovy who experiences sudden blurred vision or loss of vision should seek immediate medical attention. 

<h2>Wegovy Manufacturer Explores Semaglutide Implant </h2>

‘Use GLP-1 Carefully’, Warns Diabetologist Dr V Mohan

The <a href="https://www.healthandme.com/health-news/demand-for-wegovy-weight-loss-pills-could-increases-the-risk-of-dangerous-counterfeits-survey-article-154953255" data-type="tilCustomLink">GLP-1 medication</a> industry is in a boom. <span>Novo Nordisk</span>, the maker of GLP-1 medicines like <span>Ozempic and Wegovy</span>, is currently exploring a new way to deliver weight-loss treatment that could reduce the need for weekly injections. 

The implant, known as NPM-139, is a miniature device developed using Vivani Medical's proprietary NanoPortal technology. Rather than requiring patients to inject semaglutide every week, the tiny implant is placed beneath the skin and slowly releases the medication over an extended period. 

If successful, it could mark a significant step toward making GLP-1 drug more convenient for people living with obesity.

Health Conditions A-Z

health

wegovy-more-likely-to-cause-rare-blindness-than-ozempic-and-other-similar-drugs-recent-study-finds

wegovy

ozempic

ozempic and wegovy

novo nordisk

wegovy and naion

british journal of ophthalmology

wegovy and ozempic

wegovy blindness

wegovy eye stroke

not-lyme-disease-canada-sees-rise-in-another-tick-borne-infection-as-temperatures-increase

Not Lyme Disease, Canada Sees Rise in Another Tick-Borne Infection As Temperatures Increase

delhis-poor-aqi-monsoon-conditions-put-childrens-lungs-at-risk-ways-to-keep-kids-safe

Delhi's Poor AQI, Monsoon Conditions Put Children's Lungs at Risk: Ways to Keep Kids Safe

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

A new safety analysis has found that Wegovy, the recently launched blockbuster weight loss medication containing semaglutide, may cause a rare but dangerous eye condition that can lead to sudden and permanent vision loss. The analysis, published in the British Journal of Ophthalmology, compared Wegovy, semaglutide tablets and other GLP-1 drugs like Ozempic by examining more than 30 million reports from the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) submitted between 2017 and 2024. Scientists found a safety signal that linked semaglutide medicines to non-arteritic anterior ischemic optic neuropathy (NAION), also known as eye stroke. Wegovy More Likely To Cause Blindness Than Ozempic The signal appeared to be nearly five times stronger for Wegovy than for Ozempic, despite both medicines containing the same active ingredient, semaglutide. NAION occurs when blood flow to the optic nerve suddenly gets reduced, causing damage to the nerve responsible for transmitting visual information from the eye to the brain. The patient experiences painless vision loss in one eye. While some patients experience partial improvement, the vision loss is frequently permanent. There is currently no proven treatment to reverse the damage. Researchers state that the findings do not prove that Wegovy causes NAION. Instead, they observe a typical signal, meaning an unexpected pattern observed in a large safety database that requires immediate further investigation. Such pharmacological analyses are useful for identifying rare and adverse side effects that may not emerge during clinical trials. Why Wegovy Poses A Greater Risk Of Rare Blindness? Also read: Novo Nordisk Launches Awiqli In India: All About The World's First Once-Weekly InsulinThe stronger link observed with Wegovy and NAION compared with Ozempic has also raised new questions. Both drugs contain semaglutide, but Wegovy is prescribed at higher doses for obesity, while Ozempic is used to treat type 2 diabetes. Researchers say that factors such as higher dosing, differences in patient populations, or underlying health conditions could help explain the disparity, although more research is needed. The latest findings build on growing scientific interest in the potential eye-related risks of GLP-1 receptor agonists. Previous observational studies have also reported an increased risk of NAION among semaglutide users, prompting regulators in Europe to add the condition as a very rare side effect to semaglutide product information last year. Health experts emphasize that patients should not stop taking Wegovy without consulting their healthcare provider. For most users, the drug's benefits in managing obesity and reducing associated health risks are likely to outweigh the extremely rare risk of developing NAION. However, anyone taking Wegovy who experiences sudden blurred vision or loss of vision should seek immediate medical attention. Wegovy Manufacturer Explores Semaglutide Implant             The GLP-1 medication industry is in a boom. Novo Nordisk, the maker of GLP-1 medicines like Ozempic and Wegovy, is currently exploring a new way to deliver weight-loss treatment that could reduce the need for weekly injections. The implant, known as NPM-139, is a miniature device developed using Vivani Medical's proprietary NanoPortal technology. Rather than requiring patients to inject semaglutide every week, the tiny implant is placed beneath the skin and slowly releases the medication over an extended period. If successful, it could mark a significant step toward making GLP-1 drug more convenient for people living with obesity.

wegovy more likely to cause rare blindness than ozempic and other similar drugs, recent study finds

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Wegovy More Likely To Cause Rare Blindness Than Ozempic And Other Similar Drugs, Recent Study Finds

Not Lyme Disease, Canada Sees Rise in Another Tick-Borne Infection As Temperatures Increase

Why WHO Southeast Asia Wants To Phase Out One Of The Most Commonly Used Dental Fillings?

Omicron Sub-Lineages Likely Behind COVID Surge In India: Why Deaths Are Occurring

Health Conditions A-Z

Not Lyme Disease, Canada Sees Rise in Another Tick-Borne Infection As Temperatures Increase

Wegovy More Likely To Cause Rare Blindness Than Ozempic And Other Similar Drugs, Recent Study Finds

Delhi's Poor AQI, Monsoon Conditions Put Children's Lungs at Risk: Ways to Keep Kids Safe